Zydus Was One Of The First Applicants To Submit A Substantially Complete Anda (Abbreviated New Drugs Application) With A Paragraph Iv Certification For Mirabegron Extended-Release Tablets, 25 Mg And 50 Mg And I, Therefore,E Eligible For 180 Days Of Shared Generic Drug Exclusivity For The DrugZydus Lifesciences On Monday Said It Has Received The Usfda'S Final Nod To Market Its Generic Version Of Mirabegron Extended-Release Tablets Used To Treat Overactive Bladder, With 180 Days Of Shared Generic Drug Exclusivity. The Final Approval Granted By The Us Food And Drug Administration (Usfda) To The Company'S Us Arm Zydus Pharmaceuticals Inc Is For The Tablets Of Strengths 25 Mg And 50 Mg, It Said In A Regulatory Filing. Zydus Was One Of The First Applicants To Submit A Substantially Complete Anda (Abbreviated New Drugs Application) With A Paragraph Iv Certification For Mirabegron Extended-Release Tablets, 25 Mg And 50 Mg And I, Therefore,E Eligible Mirabegron Zydus Pharmaceuticals Inc Zydus Drug For Mirabegron Health News For 180 Days Of Shared Generic Drug Exclusivity For The Drug, It Added
